Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROOT, Switzerland--( BUSINESS WIRE )--Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20 in Tampa. The presentations cover a broad range of topics, including TTFields' multimodal mechanism of action, safety and tolerability, and health economics and outcomes research (HEOR).

Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting

ROOT, Switzerland--( BUSINESS WIRE )--Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.

Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada

ROOT, Switzerland--( BUSINESS WIRE )--Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma. The new arrays are more than 50% thinner and more than 30% lighter compared to current commercial arrays.

Novocure Secures CE Mark for New Array

A bear market is a highly opportunistic time for you to average down on fundamentally robust companies. NovoCure is a phenomenal growth stock that recently transitioned into a stalwart.

NovoCure: Entering The Next Leaping Growth Phase

Ginkgo Bioworks Holdings

Sarepta Therapeutics

The opportunities for these innovators are tremendous.

3 Unstoppable Stocks That Could Double in 5 Years

NovoCure Limited (NASDAQ:NVCR ) Q3 2022 Earnings Conference Call October 27, 2022 8:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - President & Chief Executive Officer Ashley Cordova - Chief Financial Officer Frank Leonard - Chief Development Officer Pritesh Shah - Chief Commercial Officer Conference Call Participants Greg Fraser - Truist Jason Wittes - Loop Capital Emily Bodnar - H.C. Wainwright Jason Bednar - Piper Sandler Vijay Kumar - Evercore Operator Good day and thank you for standing by.

NovoCure Limited (NVCR) Q3 2022 Earnings Call Transcript

NovoCure (NVCR) delivered earnings and revenue surprises of 16.67% and 2.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the quarter ended September 30, 2022.

Novocure Reports Third Quarter 2022 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR #TTFields--Novocure announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the ASTRO 2022 Annual Meeting.

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--A review article of anti-cancer mechanisms of action of Tumor Treating Fields has been published in the Journal of Molecular Cell Biology.

Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR #TumorTreatingFieldsTherapy--Novocure launched a campaign to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality.

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy

Disney

Trade Desk

They might not be available so cheaply for too much longer.

3 Unstoppable Stocks You Can Buy Now for Less Than $100

The Clock Is Ticking to Buy This Game-Changing Stock at a Discount

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.

Novocure to Report Third Quarter 2022 Financial Results

NovoCure faces a host of growth options along two key vectors: new geographies and other cancer applications. Despite short-term de-growth in active patients, long-term tailwinds to market share justify the company's superior multiple expansion.

NovoCure: See Past Market Myopia And Buy The Dip

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Novocure's U.S. CNS business, and is intended to renew focus on growth in Novocure's glioblastoma (GBM) business. Frank Leonard, who served as Novocure's Chief Development Officer since 2020, is named President, CNS Cancers U.S., effective September

Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business

NovoCure has maintained a large amount of institutional investors since IPO in 2015, and has nearly 78% of shares held by institutions today. Insider Ownership is high as well at 14% indicating employees have conviction in the long-term outlook of the company.

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Motley Fool contributor Brian Orelli shares why he loves this stock

Why I Own Novocure Stock (NVCR)

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure's leadership team to tour the company's U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure's groundbreaking work to extend patient survival in some of the most aggressive forms of cancer. Following the tour, Sen. Hassan met with Novocure employees to answer questions and provide an update on her work in Washington. In her remarks, Sen. Hassan spoke about the

Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility

Rexford Industrial Realty

T-Mobile US

It's not too late to snatch up some great stocks at good prices.

5 Top Stocks for August

Novocure Ltd (NASDAQ:NVCR ) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg - VP, IR William Doyle - Executive Chairman Ashley Cordova - CFO Asaf Danziger - President, CEO & Director Uri Weinberg - Chief Science Officer Pritesh Shah - Chief Commercial Officer Conference Call Participants Cory Kasimov - JPMorgan Chase & Co. Jason Bednar - Piper Sandler & Co. Gregory Fraser - Truist Securities Emily Bodnar - H.C. Wainwright & Co. Jason Wittes - Loop Capital Markets Operator Good day, and welcome to the NovoCure Q2 2022 Earnings Call.

Novocure Ltd (NVCR) CEO Asaf Danziger on Q2 2022 Results - Earnings Call Transcript

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “The second quarter was a period of solid progress, further solidifying the fundamentals of our business,” said William Doyle, Novocure's Executive Chairman. “We gen

Novocure Reports Second Quarter 2022 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields). The AACR is the world's first and largest professional organization dedicated to advancing ca

News for Novocure Stock (NVCR)